Literature DB >> 16790606

Valosin-containing protein gene mutations: clinical and neuropathologic features.

L Guyant-Maréchal1, A Laquerrière, C Duyckaerts, C Dumanchin, J Bou, F Dugny, I Le Ber, T Frébourg, D Hannequin, D Campion.   

Abstract

BACKGROUND: Hereditary inclusion body myopathy (IBMPFD) with Paget disease of bone (PDB) and frontotemporal dementia (FTD) is a rare multisystem disorder with autosomal dominant inheritance. Recently, missense mutations in the gene encoding valosin-containing protein (VCP) have been found in individuals with IBMPFD. VCP/P97, which exerts a variety of cellular functions, plays a key role in the ubiquitin-proteasome dependent degradation of cytosolic proteins and in the retrotranslocation of misfolded proteins from the endoplasmic reticulum into the cytoplasm.
METHODS: The authors describe the clinical features of two kindreds in which VCP R93C and R155C missense mutations segregate and perform a histopathologic examination of brain, muscle, bone, and liver of three subjects harboring the R155C mutation.
RESULTS: Frontotemporal dementia was present in 100% of affected subjects in Family F1 and 70% in Family F2, as compared with an average of 30% in previously described IBMPFD families. In contrast, PDB was a more inconstant clinical feature. Biochemical and histopathologic data are consistent with the hypothesis that VCP R155C mutation disrupts normal VCP function, leading to diffuse accumulation of ubiquitinated proteins within the cells.
CONCLUSIONS: VCP mutations are present in two families in which FTD is the most prominent symptom. The histopathologic study performed in patients harboring the R155C mutation supports the hypothesis that this mutation disrupts normal VCP function, leading to diffuse accumulation of ubiquitinated proteins within the cells. IBMPFD belongs to a class of genetic diseases associated with an alteration of the ubiquitin-proteasome system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790606     DOI: 10.1212/01.wnl.0000225184.14578.d3

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  43 in total

Review 1.  Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis.

Authors:  C C Weihl
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

2.  A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouse.

Authors:  Angèle Nalbandian; Katrina J Llewellyn; Mallikarjun Badadani; Hong Z Yin; Christopher Nguyen; Veeral Katheria; Giles Watts; Jogeshwar Mukherjee; Jouni Vesa; Vincent Caiozzo; Tahseen Mozaffar; John H Weiss; Virginia E Kimonis
Journal:  Muscle Nerve       Date:  2012-11-21       Impact factor: 3.217

3.  Decreases in valosin-containing protein result in increased levels of tau phosphorylated at Ser262/356.

Authors:  Philip J Dolan; Youngnam N Jin; Woong Hwang; Gail V W Johnson
Journal:  FEBS Lett       Date:  2011-10-05       Impact factor: 4.124

Review 4.  The genetics of frontotemporal lobar degeneration.

Authors:  Rosa Rademakers; Mike Hutton
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

5.  VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death.

Authors:  Michael A Gitcho; Jeffrey Strider; Deborah Carter; Lisa Taylor-Reinwald; Mark S Forman; Alison M Goate; Nigel J Cairns
Journal:  J Biol Chem       Date:  2009-02-23       Impact factor: 5.157

6.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

7.  Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia.

Authors:  S G Mehta; M Khare; R Ramani; G D J Watts; M Simon; K E Osann; S Donkervoort; E Dec; A Nalbandian; J Platt; M Pasquali; A Wang; T Mozaffar; C D Smith; V E Kimonis
Journal:  Clin Genet       Date:  2012-10-04       Impact factor: 4.438

8.  FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.

Authors:  Hazel Urwin; Keith A Josephs; Jonathan D Rohrer; Ian R Mackenzie; Manuela Neumann; Astrid Authier; Harro Seelaar; John C Van Swieten; Jeremy M Brown; Peter Johannsen; Jorgen E Nielsen; Ida E Holm; Dennis W Dickson; Rosa Rademakers; Neill R Graff-Radford; Joseph E Parisi; Ronald C Petersen; Kimmo J Hatanpaa; Charles L White; Myron F Weiner; Felix Geser; Vivianna M Van Deerlin; John Q Trojanowski; Bruce L Miller; William W Seeley; Julie van der Zee; Samir Kumar-Singh; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Eileen H Bigio; Han-Xiang Deng; Glenda M Halliday; Jillian J Kril; David G Munoz; David M Mann; Stuart M Pickering-Brown; Valerie Doodeman; Gary Adamson; Shabnam Ghazi-Noori; Elizabeth M C Fisher; Janice L Holton; Tamas Revesz; Martin N Rossor; John Collinge; Simon Mead; Adrian M Isaacs
Journal:  Acta Neuropathol       Date:  2010-05-20       Impact factor: 17.088

9.  Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis.

Authors:  Paloma González-Pérez; Elizabeth T Cirulli; Vivian E Drory; Ron Dabby; Puiu Nisipeanu; Ralph L Carasso; Menachem Sadeh; Andrew Fox; Barry W Festoff; Peter C Sapp; Diane McKenna-Yasek; David B Goldstein; Robert H Brown; Sergiu C Blumen
Journal:  Neurology       Date:  2012-11-14       Impact factor: 9.910

10.  Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease.

Authors:  Jeong-Sun Ju; Rodrigo A Fuentealba; Sara E Miller; Erin Jackson; David Piwnica-Worms; Robert H Baloh; Conrad C Weihl
Journal:  J Cell Biol       Date:  2009-12-14       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.